CDC NEWS


powered by Surfing Waves


Latest News


Covid-19 Live Updates


04 Jan 2021

Covid-19 Live Updates


Maintaining Safety with SARS-CoV-2 Vaccines


30 Dec 2020

To date, the development of mRNA vaccines for the prevention of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a success story, with no serious concerns identified in the ongoing phase 3 clinical trials


An Essential Worker’s List of Pandemic Chores for the Kids


29 Dec 2020

Sorry I had to leave before you woke up. You’re right, it isn’t fair. Please empty the dishwasher today. And brush your teeth. Remember to feed the dog. He will die if no one remembers to do this.


Phase 3 trial of Novavax investigational COVID-19 vaccine opens


28 Dec 2020

The Phase 3 trial of another investigational coronavirus disease 2019 (COVID-19) vaccine has begun enrolling adult volunteers. The randomized, placebo-controlled trial will enroll approximately 30,000 people at approximately 115 sites in the United States and Mexico. It will evaluate the safety and efficacy of NVX-CoV2373, a vaccine candidate developed by Novavax, Inc., of Gaithersburg, Maryland. Novavax is leading the trial as the regulatory sponsor.


Older Adults’ Perspectives on a COVID-19 Vaccine


23 Dec 2020

As of December 4, 2020, cases of novel coronavirus disease 2019 (COVID-19) have topped 14.3 million in the US with nearly 300 000 associated deaths. While mitigation measures such as social distancing, use of face coverings, and avoidance of crowds can help keep case counts in check, a safe and effective COVID-19 vaccine will be essential to ending the pandemic.




Articles


Association of Major Depressive Symptoms With Endorsement of COVID-19 Vaccine Misinformation Among US Adults


21 Jan 2022

Key Points Question Are major depressive symptoms associated with increased risk of believing common misinformation about COVID-19 vaccines among US adults? Findings In this survey study including 15 464 US adults, people with moderate or greater major depressive symptoms on an initial survey were more likely to endorse at least 1 of 4 false statements about COVID-19 vaccines on a subsequent survey, and those who endorsed these statements were half as likely to be vaccinated. Meaning These findings suggest another potential benefit of public health efforts to address depressive symptoms, namely reducing susceptibility to misinformation.




Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves


30 Dec 2021

On November 24, 2021, a SARS-CoV-2 variant of concern, Omicron (B.1.1.529), was identified in South Africa as responsible for a fourth wave of COVID-19.1,2 The high number of spike mutations has raised concerns about its ability to evade vaccine and spread.3,4 We assessed hospitalized patients with a positive SARS-CoV-2 test result during the fourth wave compared with previous waves.




Why Parents Still Hesitate to Vaccinate Their Children Against COVID-19


15 Dec 2021

As of early December, more than 2.3 million children aged 5 to 11 years had developed COVID-19 and 209 had died. Although a vaccine that’s 90.7% effective in preventing the illness was authorized for younger kids in late October, these figures apparently aren’t convincing enough to persuade many parents to vaccinate their children.




Understanding Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination


04 Nov 2021

The current surge in infections with the SARS-CoV-2 Delta variant has made it clear to health care workers and the public alike that fully vaccinated people remain at risk for SARS-CoV-2 infections. It is also apparent that breakthrough infections in fully vaccinated people can sometimes be serious. As of October 21, 2021, for example, 35% of the 519 patients hospitalized with COVID-19 in Massachusetts had been fully vaccinated.1 Furthermore, multiple reports have documented that if fully vaccinated individuals do become infected, their viral loads may be as high as the levels seen in unvaccinated individuals.




Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans


06 Oct 2021

Question What was the COVID-19 vaccination coverage and estimated mRNA COVID-19 vaccine effectiveness (VE) among US veterans in the first 3 months following vaccine rollout? Findings In this case-control study including 6 647 733 veterans, 23% of veterans received at least 1 COVID-19 vaccination during the first 3 months of vaccine rollout. VE against infection was estimated to be 95% for full vaccination; estimated VE against COVID-19-related hospitalization was 91%, and there were no COVID-19–related deaths among fully vaccinated veterans. Meaning These findings suggest that early vaccination rollout for veterans was efficient, and estimated VE was high for this diverse US population.




Enroll for Free